Background: About 1 in 4 veterans have diabetes, and many also have chronic kidney disease (CKD).Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, is approved for the treatment of diabetes.The purpose of this study was to evaluate the effectiveness of empagliflozin on hemoglobin A ...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!